Hye Ryun Kim

Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer

Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2016 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 976 citations · Full text

Medicine, Oncology, Pharmacology +13

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Charles M. Rudin, Mark M. Awad, Alejandro Navarro et al. · Journal of Clinical Oncology · 2020 · 759 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino et al. · Journal of Clinical Oncology · 2018 · 515 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Thoracic Oncology · 2021 · 372 citations · Full text

Medicine, Oncology, Pharmacology +12